[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"organoid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:organoid":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,67,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100470320","establishment-of-an-ex-vivo-tumor-collection-of-triple-negative-breast-cancers-in-order-to-validate-the-interest-of-innovative-therapies-and-the-search-for-predictive-biomarkers-of-response-to-treatment-100470320",false,"NCT05404321","Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment","TRIPLEX","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Patient with early stage (I-III) triple negative breast cancer who needs to have clips placed before neoadjuvant chemotherapy\n* Patient affiliated to a social security system\n* Proficiency in French language,\n* Patient having signed the consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant women\n* Persons deprived of liberty or under guardianship (including curatorship)\n* History of any other clinically active malignancy in the last 5 years prior to inclusion","FEMALE","18 Years",{"count":19,"type":20},163,"ESTIMATED","OBSERVATIONAL","Initially described in 2009 on LGR5 positive stem cells from intestine, organoids correspond to a 3D cell culture that preserves the organization and part of the initial function of the organ from which the cells were derived. They use the proliferation and differentiation properties of stem cells cultured in a three-dimensional matrix.\n\nThese principles have been adapted to many human organs, including the breast. These culture conditions have thus allowed the establishment of cancer organoid lines that have the advantages of rapid amplification, a high rate of establishment success and unlimited proliferation potential. They are transfectable and cryopreservable. They are very close morphologically and genetically to the tumor from which they derive. Very recently, the in vivo response of orthotopic xenograft models of breast cancer organoids has been correlated to the in vitro response of these same organoids. In addition, the in vitro response of various of these models to PARP inhibitors was linked to the presence of the BRCA1\u002F2 mutant signature, highlighting the potential of these models to predict patient response to these treatments.\n\nFurthermore, one study demonstrated the value of using organoids derived from metastatic gastrointestinal tumors to predict patient response to cancer treatments (100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predictive value.",[24,25],"Triple Negative Breast Cancer","Organoid","RECRUITING","2026-03-17",{"date":29,"type":30},"2026-03-19","ACTUAL",{"date":32,"type":30},"2023-01-09",{"date":34,"type":20},"2028-12",{"name":36,"class":37},"Centre Francois Baclesse","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":38},"100576260","drug-response-testing-and-repurposing-using-glioblastoma-organoid-100576260","NCT06782984","Drug Response Testing and Repurposing Using Glioblastoma Organoid","Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy","Inclusion Criteria:\n\n* primary or recurrent glioblastoma\n* patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy\n* sufficient tumor sample is available for organoid culture\n\nExclusion Criteria:\n\n* patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery\n* failed to obtain MRI scan after CCRT\n* patients refusal","ALL",{"count":48,"type":20},150,"1 Year","The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.",[52,25],"Glioblastoma",[54,55,56,57],"organoid","glioblastoma","GBO","drug-screening","2025-01-14",{"date":60,"type":30},"2025-01-20",{"date":62,"type":30},"2021-08-18",{"date":64,"type":20},"2030-12",{"name":66,"class":37},"Chungnam National University Hospital",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":74,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100557331","observation-of-clinical-consistency-of-organoid-chips-drug-sensitivity-in-chemotherapy-for-pca-with-visceral-metastasis-100557331","NCT06536725","Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis","Observation of Clinical Consistency of Organoid-on-chips Drug Sensitivity Detection in Chemotherapy for Prostate Cancer Patients With Visceral Metastasis","Inclusion Criteria:\n\n1. Patients with visceral metastasis of prostate cancer diagnosed clinically or pathologically;\n2. Age ≥ 18 years old;\n3. ECOG score ≤ 2 points or ECOG score 3-4 points due to tumor progression;\n4. Normal liver and kidney function, serum transaminase ALT\\\u003C66 U\u002FL, AST\\\u003C36 U\u002FL, total bilirubin\\\u003C22 umol\u002FL, creatinine\\\u003C106 umol\u002FL, urea nitrogen\\\u003C6.1 mmol\u002FL; Normal bone marrow function: neutrophil count ≥ 1800\u002Fmm3 and platelet count ≥ 100000\u002Fmm3;\n5. Can obtain surgical or biopsy samples;\n6. Patients voluntarily join this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with severe heart, liver, kidney, and peripheral nervous system diseases, as well as autoimmune diseases such as hyperthyroidism and hypothyroidism; Systemic lupus erythematosus, etc;\n2. Patients who are unable to obtain tissue samples;\n3. Subjects with active pulmonary tuberculosis (TB);\n4. Subjects who are preparing for or have previously undergone tissue\u002Forgan transplantation;\n5. Exclusion criteria are not listed, but the researchers believe that patients who are not suitable to participate in this clinical study.","MALE",{"count":76,"type":20},35,"This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plans.",[79,25],"Prostate Cancer","2024-08-02",{"date":82,"type":30},"2024-08-05",{"date":84,"type":30},"2024-06-01",{"date":86,"type":20},"2025-12-31",{"name":88,"class":37},"Tianjin Medical University Second Hospital",2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":46,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":98,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":38},"100360901","patient-derived-organoids-of-lung-cancer-to-test-drug-response-100360901","NCT03979170","Patient-derived Organoids of Lung Cancer to Test Drug Response","Inclusion Criteria:\n\n* Histologically proven lung cancer\n* Age ≥ 18\n* Written informed and signed consent\n* Accessible to biopsy and\u002For surgery sample of metastasis and\u002For primitive tumour\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Not able to give informed consent (language, intellectual capacities, etc.)\n* Not accessible to biopsy and\u002For surgery sample\n* Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.",{"count":97,"type":20},50,"1 Day","This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.",[101,25],"Lung Cancer","2024-05-31",{"date":104,"type":30},"2024-06-03",{"date":106,"type":30},"2019-04-01",{"date":108,"type":20},"2029-12-30",{"name":110,"class":37},"University Hospital, Geneva"]